Pharmaceuticals
Everest Medicines Announces Completion of Patient Enrollment in Nefecon® China Open Label Extension Study
SHANGHAI, August 1, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today the completion of patient enrollment for theChi...
2023-08-01 08:47
2772
Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density
SUZHOU, China, July 31, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has receiv...
2023-07-31 08:10
2466
Daewoong Pharmaceutical submits a new drug application for Fexuprazan in China challenging the world's largest market for anti-ulcer drugs
– Daewoong Pharmaceutical, "Expecting the smooth approval with the successful phase 3 clinical trial inChina aiming to reach 100 countries by 2027" SEOUL, South Korea, July 31, 2023 /PRNewswire/ -- Daewoong Pharmaceutical's domestically produced drug no. 34 Fexuprazan, a newly developed one for t...
2023-07-31 08:00
3152
Latest Updates of 7 Viva's Portfolio Companies
HONG KONG, July 28, 2023 /PRNewswire/ -- In the face of ever-changing circumstances, technological innovation remains the eternal driving force behind the long-term growth of biopharmaceutical companies. It continuously breathes life into these enterprises, enabling them to successfully transitio...
2023-07-28 19:31
7605
HANQUYOU Marks 3rd Anniversary with Brilliant Achievements
* HANQUYOU is the China-developed biosimilar with the most marketing approvals, covering 41 countries and regions * The launch of HANQUYOU kicks off the competition between Chinese pharmaceutical companies and the world's bio-pharmaceutical companies in biosimilar monoclonal antibodies * He...
2023-07-28 15:53
4327
GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION'S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030
– Gilead expands the ALL4LIVER Grant, Providing Grant Funding to Organizations inAfrica, South America, Asia and Oceania, Europe and North America – – Themed 'Test. Link. Prioritize', the Grant Program will Target Projects Focusing on Viral Hepatitis Elimination by 2030 – SINGAPORE, July 28, ...
2023-07-28 12:00
6025
Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development
HONG KONG, Germantown, Md. and SUZHOU, China, July 28, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced tha...
2023-07-28 11:56
3358
61.6 percent of Young Thai Women Put off by Pap Smears: BGI Genomics Cervical Cancer Survey
* 61.6% of Thai women aged 21-25 years deterred by pap smears which is higher
than the global average of 43.5% HONG KONG, July 28, 2023 /PRNewswire/ -- Only
28.5% of Thai women are diagnosed at stage I of cervical cancer when survival
rates are highest, according to a study
2023-07-28 08:37
1906
Clarivate Enhances Patient Data Intelligence Solution with Addition of German Hospital Prescribing Insights
New data captures German prescribing insights providing researchers with aggregated, anonymised specialty prescribing habits across brands and diseases LONDON, July 27, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they ca...
2023-07-27 15:00
2062
Acceptance Of Clinical Trial Application For The Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In China And Overseas Clinical Trial Progress
TAIZHOU, China, July 27, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Board") is pleased to announce that the Group has recently received the notice of acceptance (acceptance number: CXSL2300518) issued by National Medical Products Administration ("NMPA"), pursuant to which the c...
2023-07-27 10:57
5546
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China
Everest transforms into a commercial-stage innovative biopharmaceutical company SHANGHAI, July 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicin...
2023-07-27 08:10
2912
YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023
Total revenues increase by 36.3% year-over-year; gross margin improves to 77.7%; balance sheet remains robust Company's PIKA rabies vaccine approved for Phase III clinical trials in Singapore, the Philippines, and Pakistan; interim results expected early next year GAITHERSBURG, Md., July 27, 20...
2023-07-27 05:00
4866
Hummingbird Bioscience Initiates HMBD-001 Phase IB Trials in Australia and Partners with Omico to Accelerate Clinical Development
* Hummingbird Bioscience has initiated two clinical trials in Australia evaluating HMBD-001 in patients with squamous non-small cell lung cancer and patients with genetic aberrations in HER3 signaling * Hummingbird Bioscience has identified genetic signatures that are predictive of response t...
2023-07-27 04:00
2497
World's first*1 report: A potential effectiveness of Plasmacluster Technology that may induce brain activation
Validation of the mechanism of its enhancing effect on human work performance by measuring brain function *2 OSAKA, Japan, July 26, 2023 /PRNewswire/ -- Sharp Corporation conducted collaborative research on its Plasmacluster technology, with Dr.Goichi Hagiwara , Associate Professor, Faculty of Hu...
2023-07-26 14:15
2088
RemeGen's Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren's Syndrome: Findings Published in Prestigious Rheumatology Journal
YANTAI, China, July 25, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
2023-07-25 16:00
2432
Clinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV Science
HANGZHOU and SHAOXING, China, July 25, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Shanghai Public Health Clinical Center presented clinical results of ASC22 (Envafolimab) in combination with Chidamide for functional cure of human immunodeficiency virus...
2023-07-25 08:10
2965
Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
* Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients inEurope die annually from the disease² * If approved by the European Commission, ORSERDU would be the first an...
2023-07-21 23:44
6401
Saphnelo now available in Malaysia as an add-on treatment for adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)
KUALA LUMPUR, Malaysia, July 21, 2023 /PRNewswire/ -- AstraZeneca's Saphnelo ( anifrolumab) has now become available as add-on treatment for adult patients in Malaysia with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE) following insufficient response to sta...
2023-07-21 10:00
2766
Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed with LNK01004 in Phase Ib Clinical Study
HANGZHOU, China, July 21, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first patient with atopic dermatitis in a Phase Ib clinical trial of its innovative drug LNK0100...
2023-07-21 08:00
3743
Viva Biotech's Portfolio Company Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs
WATERTOWN, Mass., July 20, 2023 /PRNewswire/ -- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research a...
2023-07-20 19:15
2995
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 319 media titles]
2026-02-16 10:00
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 316 media titles]
2026-02-19 14:30
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Tower Capital Asia announces majority investment in V-Key - a leader in digital identity and mobile application security
[Picked up by 265 media titles]
2026-02-13 01:52
Appier Delivers Record Results Driven by Agentic AI Innovation
[Picked up by 263 media titles]
2026-02-13 17:03Most Read
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
8093
Cboe Launches Nearly 24-Hour Trading in Russell 2000 Index Options
2026-02-13 07:30
7371
Appier Delivers Record Results Driven by Agentic AI Innovation
2026-02-13 17:03
6861